Key clinical point: Fludarabine, cyclophosphamide, and rituximab should be first-line therapy for patients with chronic lymphocytic leukemia (CLL) without TP53 disruption.
Major finding: All patients diagnosed with CLL should be tested for TP53 disruption.
Study details: A guideline developed by the British Society for Haematology offering recommendations for CLL treatment outside clinical trials.
Disclosures: The guideline development was supported by the British Society for Haematology. The UK CLL Forum is a registered charity that receives funding from a number of pharmaceutical companies.
Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460.
This Week's Must Reads
Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.
Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004
Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282
Disparities in ALL treatment toxicity, Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939
Leukemia risk after maternal contraception use, Hargreave M et al. Lancet Oncol. 2018 Sep 6. doi: 10.1016/S1470-2045(18)30479-0
Must Reads in CLL
First-line ibrutinib has long-term survival benefit, Barr PM et al. Haematologica. 2018;103(9):1502-10.
Obinutuzumab plus venetoclax compares well with established CLL therapies, Cramer P et al. Lancet Oncol. 2018 Aug 13. doi: 10.1016/S1470-2045(18)30414-5.
Caution urged over real-world bleeding risk with ibrutinib, Kunk PR et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 15. doi: 10.1016/j.clml.2018.07.287
New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460
Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.